Claims

1. A method for treating a subject suffering from or believed to be suffering from trauma-hemorrhage, said method comprising providing the subject with at least one isolated or synthetic peptide, or functional analogue or derivative thereof, of smaller than 30 amino acids, wherein said peptide is smaller than 7 amino acids.

2. A method according to claim 1 wherein said peptide consists of 2 to 6 amino acids.

3. A method according to anyone of claims 1 to 2 wherein said peptide consists of 3 to 5 amino acids.

4. A method according to anyone of claims 1 to 3 wherein said peptide consists of 4 amino acids.

5. A method according to anyone of claims 1 to 4 wherein said treatment of trauma-hemorrhage also comprises providing said subject with blood or blood products such as red blood cells (RBCs), platelets, plasma, or combinations thereof.

6. Use of at least one isolated or synthetic peptide, or functional analogue or derivative thereof, of smaller than 30 amino acids for the production of a pharmaceutical composition for the treatment of a subject suffering from or believed to be suffering from trauma-hemorrhage.

7. Use according to claim 6 wherein said peptide is smaller than 15 amino acids.

8. Use according to claim 6 or 7 wherein said peptide is smaller than 7 amino acids.

9. Use according to anyone of claims 6 to 8 wherein said peptide consists of 2 to 6 amino acids.

10. Use according to anyone of claims 6 to 9 wherein said peptide consists of 3 to 5 amimo acids.

11. Use according to to anyone of claims 6 to 10 wherein said peptide consists of 4 amino acids.

12. Use according to anyone of claims 6 to 11 wherein said said treatment of trauma-hemorrhage also comprises providing said subject with blood or blood products such as red blood cells (RBCs), platelets, plasma, or combinations thereof.

Claims

1. Use of at least one isolated or synthetic tetrapeptide selected from the group consisting of LQGV, AQGV and LAGV and functional derivatives thereof wherein an L-amino acid residue is substituted with a D-amino acid, or a pharmaceutically acceptable acid- or base addition salt thereof, for the production of a pharmaceutical composition for the treatment of a subject suffering from or believed to be suffering from trauma-hemorrhage.

2. Use according to claim 1, wherein said peptide is selected from the group consisting of LQGV, AQGV and LAGV.

3. Use according to claim 1 or 2, comprising the use of a mixture of (i) a tetrapeptide selected from the group consisting of LQGV, AQGV and LAGV and (i) a further peptide capable of reducing pro-inflammatory cytokine levels in an animal model of trauma-hemorrhage or hemorrhagic shock.

4. Use according to any one of claims 1 to 3, wherein said tetrapeptide is LQGV.

5. Use according to any one of claims 1 to 3, wherein said tetrapeptide is AQGV.

6. Use according to any one of claims 1 to 3, wherein said tetrapeptide is LAGV

7. Use according to anyone of claims 1 to 6, wherein said treatment of trauma-hemorrhage also comprises providing said subject with blood or blood products such as red blood cells (RBC's), platelets, plasma, or combinations thereof.